CYCN Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (25 Apr 2024 @ 16:00):

Stats
Today's Volume	442.00
Average Volume	2 856.00
Market Cap	8.24M
EPS	$0 ( 2024-03-27 )
Next earnings date	( $0 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.560
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-04	Chicko Rhonda M.	Sell	0	Common Stock
2024-01-01	Hecht Peter M	Buy	15 000	Common Stock
2024-01-01	Graul Regina Margaret	Buy	50 000	Common Stock
2023-11-30	Katabi Dina	Sell	0	Common Stock
2023-11-30	Higgins Michael J	Sell	0	Common Stock

INSIDER POWER
100.00
Last 100 transactions
Buy: 5 326 508 \| Sell: 727 933

Cyclerion Therapeutics Correlation

10 Most Positive Correlations
EXFO	0.954
GAME	0.946
VERO	0.942
LPCN	0.941
TA	0.933
KBAL	0.933
CTRN	0.929
ECHO	0.927
IIN	0.927
HEPA	0.925

10 Most Negative Correlations
SMH	-0.909
ATVI	-0.898
VTRU	-0.894
SGLB	-0.892
PT	-0.89
BEEM	-0.889
ALDX	-0.886
ADTN	-0.885
BSET	-0.882
VIASP	-0.878

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Cyclerion Therapeutics Financials

Annual	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-8.99

Q4	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-0.680

Q3	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-3.36

Q2	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-1.830

Financial Reports:

No articles found.

Cyclerion Therapeutics

Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes, as well as Alzheimer's disease with vascular pathology; and Phase 1 trials diagnosed with schizophrenia in adults. It is also developing Praliciguat, an orally administered systemic sGC stimulator, which is in Phase II studies to treat resistant hypertension and diabetic nephropathy; Olinciguat, an orally administered vascular sGC stimulator that is in Phase II studies for the sickle cell disease; and CY3018 for the treatment of disorders of the CNS. It has license agreement with Akebia Therapeutics, Inc. for the development, manufacture, medical affairs, and commercialization of pharmaceutical products, including pharmaceutical compound, and other related products and forms. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.